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Abstract
Background: Kiom-18 is a novel composition of Cinnamomum cassia, Pinus densiflora, Curcuma longa and Glycyrrhiza
glabra. Curcuma longa and Glycyrrhiza glabra, which are traditional medicines in Asia, have been reported to
demonstrate preventive effects against atherosclerosis; however, they have not yet been developed into functional
atherosclerosis treatments. We therefore studied the anti-atherosclerotic effects and possible molecular mechanisms of
Kiom-18 using vascular smooth muscle cells (VSMCs).
Methods: To assess the anti-proliferative effect of Kiom-18 in vitro, we performed thymidine incorporation, cell cycle
progression, immunoblotting and immunofluorescence assays in VSMCs stimulated by platelet derived-growth factor
(PDGF)-BB. In addition, we used LDLr knockout mice to identify the effects of Kiom-18 as a preliminary result in an
atherosclerosis animal model.
Results: Kiom-18 inhibited platelet-derived growth factor (PDGF)-BB-stimulated-VSMC proliferation and DNA synthesis.
Additionally, Kiom-18 arrested the cell cycle transition of G0/G1 stimulated by PDGF-BB and its cell cycle-related proteins.
Correspondingly, the level of p27kip1 expression was upregulated in the presence of the Kiom-18 extract. Moreover, in an
atherosclerosis animal model of LDLr knockout mice, Kiom-18 extract showed a preventive effect for the formation of
atherosclerotic plaque and suppressed body weight, fat weight, food treatment efficiency, neutrophil count, and
triglyceride level.
Conclusions: These results indicate that Kiom-18 exerts anti-atherosclerotic effects by inhibiting VSMC proliferation via
G0/G1 arrest, which upregulates p27
Kip1 expression.
Keywords: Anti-atherosclerotic activity, Vascular smooth muscle cell, Cell cycle, Cyclin-dependent kinase inhibitor,
Kiom-18
Background
The proliferation of vascular smooth muscle cells (VSMCs)
is one of the most important pathogenic mechanisms in
the formation of atherosclerotic plaque [1, 2]. This abnor-
mal proliferation contributes to cardiovascular disease,
including atherosclerosis, balloon angioplasty-induced re-
stenosis, and hypertension [2–5]. VSMC proliferation is
regulated by the cell cycle, which is a complex and stepwise
process, via the regulation of cyclin-dependent kinase
(CDK)/cyclin complexes and CDK inhibitors (CKIs) [6, 7].
Specific phases in cell cycle progression are regulated by
the formation of a complex with the catalytic subunit of
CDKs [8, 9]. Upon stimulation, the G1 phase of quiescent
VSMCs leads to the S phase via the regulation of CDK2/
cyclin E1 and CDK4/cyclin D1 complexes in addition to
CDK inhibitors such as p21, p53, p27 and p16. This
progression results in the hyper-phosphorylation of retino-
blastoma protein (Rb) and the dissociation of transcription
factor E2F, which initiates the transcription of genes
required for DNA synthesis [10, 11]. In previous studies,
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upregulating p21 and p27 expression has been shown to
arrest cells at the G0/G1 phase to prevent the development
of atherosclerosis [12–15].
The topic of this study, Kiom-18, is a novel composition
of four herbal components: Chinese cinnamon (Cinnamo-
mum cassia), Japanese red pine (Pinus densiflora), tur-
meric (Curcuma longa) and licorice (Glycyrrhiza glabra).
These four herbal components of Kiom-18 have been pre-
viously reported to exhibit beneficial in vitro and in vivo
effects as traditional medicines. C. cassia, a traditional
Chinese herbal medicine, has been used in herbal formu-
las, such as Ge-Gen-Tang (Kakkon-to) and Sini Tang, to
manage various diseases, including colds, congestion,
fever, heart failure and myocardial infarction [16–21]. P.
densiflora, a plant that is common throughout Asia, has
traditionally been used as a tea, food ingredient, or folk
medicine [22, 23]. C. longa has been widely used as a trad-
itional medicine in Southeast Asia, and curcumin is its
major active component [24]. In addition, C. longa,
Japanese alder (Alnus japonica) and Massa Medicata
Fermentata (medicated leaven) make up gambigyeong-
sinhwan (4), which has been used to treat obesity in local
Korean clinics; the mechanism of its anti-obesity effect
has recently been established [25]. Traditionally, G. glabra,
a medicinal herb cultivated in several regions of the world,
has been used in the treatment of kidney stones, hepatitis
C, and cough and stomach ailments [26, 27]. In a recent
report, C. cassia was demonstrated to have anti-cancer
effects, via the bioactive compound cinnamaldehyde
isolated from the stem bark; anti-diabetic effects, due to
the inhibition of fibronectin, monocyte chemoattractant
protein-1 and interleukin-6 by its active components, anti-
osteoporosis effects, as found in Jasin-hwan-gagambang
(BHH10), a formula that includes C. cassia, and anti-
inflammatory effects, through the blockage of NF-kB by
cinnamaldehyde [28–32]. P. densiflora exerts anti-oxidant
activity in a variety of applications, anti-cancer activity in
human oral squamous cell carcinoma using an oil formula-
tion of P. densiflora leaf and hepatoprotective activity by
regulating lipid accumulation and oxidative stress in the
liver [33–35]. Recently, C. longa and G. glabra have been
reported to have beneficial effects. C. longa may be useful
as a natural supplement for the treatment of metabolic
syndrome: it has anti-diabetic effects by inhibiting angio-
tensin converting enzyme, and an ethanolic extract exerts
a neuroprotective effect in the hippocampus [36, 37].
Moreover, G. glabra has hepatoprotective effects in com-
bination with glycyrrhizin and silymarin, which are metab-
olites of G. glabra and milk thistle (Silybum marianum),
respectively, and anti-tubercular effects for its extract that
includes active compounds [38, 39]. Among these individ-
ual components of Kiom-18, C. longa and G. glabra have
been reported in many studies to prevent atherosclerosis
by the suppression of low-density lipoprotein (LDL)
oxidation; however, to date, they have not been developed
as supplemental foods for the treatment of atherosclerosis
[40–45]. Therefore, we studied the anti-atherosclerotic
effects of a novel composition including C. longa and G.
glabra for its potential use in supplementary foods. We
also examined the effects on VSMC proliferation and the
molecular mechanism of its anti-proliferative action.
Methods
Materials and reagents
The bark from Cinnamomum cassia (Nees & T.Nees)
J.Presl, needles from Pinus densiflora Siebold et Zuccarini,
root from Curcuma longa Linne, and root from
Glycyrrhiza glabra Linne were purchased from an herb
market in Yeongcheon, Korea. All plant material identities
were confirmed by Dr. Ki Hwan Bae of the College of
Pharmacy, Chungnam National University (Daejeon,
Korea); all voucher specimens have been stored in the
herbal bank at the Korea Institute of Oriental Medicine
(Daejeon, Korea). Distilled water was filtered through a
0.45-μm membrane filter from ADVANTEC (Tokyo,
Japan) before analysis. Phosphate-buffered saline PBS) and
fetal bovine serum (FBS) were obtained from HyClone
(Logan, UT, USA). Dulbecco’s modified Eagle’s medium
(DMEM) was purchased from Lonza (Walkersville, MD,
USA). Trypsin/EDTA and penicillin/streptomycin were
purchased from Gibco (Grand Island, NY, USA).
Anti-phospho-extracellular signal regulated kinase 1/2
(ERK1/2), anti-ERK1/2, anti-phospho-phospholipase
C-γ1 (PLCγ1), anti-phospho-p38, anti-p38, anti-phos-
pho-phosphatidylinositol 3-kinase-linked protein kinase B
(Akt), anti-Akt, anti-phospho-c-Jun N-terminal kinase
(JNK), anti-JNK, anti-CDK2, anti-CDK4, anti-cyclin D1,
anti-cyclin E1, anti-phospho-retinoblastoma protein (Rb),
anti-proliferating cell nuclear antigen (PCNA) (PC10), and
anti-β-actin antibodies were purchased from Cell Signal-
ing Technology Inc. (Beverly, MA, USA). Cell Counting
Kit-8 (CCK-8) was purchased from Dojindo Molecular
Technologies (Rockville, MD, USA). Platelet-derived
growth factor (PDGF)-BB was obtained from KOMABIO-
TECH (Seoul, Korea). All other chemicals were of analyt-
ical grade.
Animals
Male LDL-receptor knockout (Ldlr KO, strain name:
LdB6.129S7-Ldlrtm1Her/J, C57BL/6 background) mice
were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA) and acclimated for 1 week at a
temperature of 25 ± 2 °C, humidity of 55 ± 5 % and
12:12 h light–dark cycle. After the mice in the negative
control group were given unlimited access to AIN-76A
(AIN-76A: casein 200, DL-methionine 3, cornstarch 150,
sucrose 500, fiber 50, corn oil 50, AIN mineral mix 35,
AIN vitamin mix 10, choline bitartrate 2 g/kg) for
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2 weeks, they were then fed a Western diet for 14 weeks
(fat 21 %, cholesterol 0.15 %, no cholate). The mice in
the Kiom-18 group (1 g/kg) were fed a Western diet by
gavage (oral administration) and were fed at the same
time daily. The animal experiments were conducted in ac-
cordance with the Korea Institute of Oriental Medicine
Care Committee Guidelines and were accepted by the
Korea Institute of Oriental Medicine (KIOM) Care and
Use Committee. The animals were cared for in accordance
with the dictates of the National Animal Welfare Law of
Korea.
Preparation of the Kiom-18 extract
A total of 2470 g Kiom-18, including C. cassia, P. densi-
flora, C. longa and G. glabra (Individual ratio = 1.3 : 1.3 :
1.4 : 1), was placed in 25 L of distilled water and then ex-
tracted by heating for 3 h at 115 °C (Gyeongseo Extractor
Cosmos-600, Inchon, Korea). The extract of Kiom-18 was
filtered using a standard test sieve of 150 μm (Retsch,
Haan, Germany), freeze-dried and maintained by desicca-
tors at 4 °C until use.
Cell culture
Rat aortic VSMCs, isolated by enzymatic dispersion, were
obtained from Biobud Co. (Seongnam-si, Gyeonggi-do,
Korea). The isolation of VSMCs has been previously re-
ported [46]. The cells were cultured in DMEM (supple-
mented with 10 % FBS, 100 IU/mL penicillin, 100 μg/mL
streptomycin, 8 mM HEPES, and 2 mM L-glutamine) at
37 °C in a humidified atmosphere of 95 % air and 5 %
CO2. The purity of the cultures was confirmed based on
the immunocytochemical localization of α-smooth muscle
actin. Our experiment used the VSMCs of passages 5–7.
Cell proliferation assay
Cell proliferation was measured as previously described
[47]. VSMCs were examined using colorimetric WST-1
assays (CCK-8; Dojindo Molecular Technologies, Rock-
ville, MD, USA). VSMCs were seeded into 96-well
culture plates at 4 × 104 cells/mL and then cultured in
complete media (DMEM containing 10 % FBS) at 37 °C
for 24 h. After reaching approximately 70 % confluence,
VSMCs were incubated with serum-free medium for
24 h, treated with Kiom-18 of various concentrations for
another 24 h in new fresh serum-free medium, and stim-
ulated by PDGF-BB at a concentration of 25 ng/mL.
After 24 h, WST-1 reagent (WST-1 premix) was added
to the medium, and the cells were incubated for an
additional 2 h. The absorbance was measured at 450 nm
using a microplate reader (Packard Instrument Co.,
Downers Glove, IL, USA). All experimental procedures
were performed as per the manufacturer’s instructions,
and the results are expressed as the percentage of the
PDGF-BB-stimulated control.
DNA synthesis
The measurement of DNA synthesis was monitored
using a [3H]-thymidine incorporation assay, as previ-
ously described [48]. The conditions of this assay were
as described for the cell proliferation assay. [3H]-thymi-
dine (2 μCi/ml) was added 4 h before harvesting under
conditions stimulated by PDGF-BB 25 ng/ml in serum-
free medium. The reaction was stopped by aspirating the
medium and subjecting the cultures to sequential
washes with PBS containing ethanol/ether (1:1, v/v) and
10 % trichloroacetic acid on ice. Acid-insoluble product
with [3H]-thymidine was extracted in 250 μl of 0.5 M
NaOH/well, and this solution was combined with 3 ml
of scintillation cocktail (Ultimagold, Packard Bioscience,
Meriden, CT, USA) and measured using a liquid scintil-
lation counter (LS3801, Beckman, Düsseldorf, Germany).
Cell cycle progression analysis
The cell cycle progression was measured as previously
described [49]. This assay procedure was the same as
that described for the cell proliferation assay. After
stimulation with PDGF-BB 25 ng/mL for 24 h, the
harvested cells were suspended in 1 mL of PBS and fixed
with 70 % ethanol for 48 h. In the fixed cells, the ethanol
was removed, and the pellets were then stained with
propidium iodide (PI) solution (50 μg/mL PI in sample
buffer containing 100 μg/mL RNase A). Each sample
was incubated at room temperature for 1 h. The PI-
DNA complex of each cell nucleus was measured using
a FACSCalibur flow cytometer (Becton, Dickinson and
Co., Franklin Lakes, NJ, USA). The individual nuclear
DNA content was determined by the incorporated PI
fluorescence intensity. The rate of the cell cycle at the
G0/G1, S, and G2/M phases was determined by analysis
using Modfit LT software (BD, Topsham, ME, USA).
Immunoblotting
Protein measurement by immunoblotting was performed
as previously described [50]. VSMCs were stimulated
with PDGF-BB (25 ng/mL) for 5 min for ERK1/2 and
PLCγ1, 10 min for JNK and p38, and 15 min for Akt
phosphorylation assays. For the measurements of CDK2,
CDK4, cyclin D1, cyclin E1, p27 and PCNA expression,
and Rb phosphorylation, VSMCs were stimulated with
PDGF-BB (25 ng/mL) for 24 h. Each of the proteins
were normalized with β-actin or the respective total pro-
teins. The band intensities were quantified using Scion
Image for Windows (Scion Corp., Frederick, MD, USA).
Immunofluorescence staining
VSMCs were cultured in 24-well plates that included
cover slips at 8 × 104 cells/mL and were then stimulated
with PDGF-BB 25 ng/mL for 24 h, after which they were
fixed with 2 % paraformaldehyde in PBS for 10 min and
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then blocked with 5 % bovine serum albumin in PBS for
1 h at room temperature. The cells were stained with pri-
mary antibodies (anti-p27) for 2 h and then with Alexa
Fluor 555-conjugated secondary antibody (Cell Signaling
Technology Inc., Beverly, MA, USA). The cells were
mounted in PI solution for 10 min and observed using a
fluorescence microscope (TH4-200; Olympus Optical Co.
Ltd., Tokyo, Japan).
Atherosclerotic lesion analysis
The mice were anesthetized with an intraperitoneal in-
jection of ketamine (50 mg/kg) and xylazine (6.7 mg/kg).
After perfusion-fixing with 10 % buffered formalin, the
aortic arches were transversely sectioned and stained
with hematoxylin and eosin (H&E) as previously de-
scribed [51, 52].
Plasma lipid analysis
A Hitachi 7080 (Tokyo, Japan) biochemical analyzer
was used to measure the serum concentrations of tri-
glyceride (TG), aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), glucose, total cholesterol
(T-C), high-density lipoprotein-cholesterol (HDL-C)
and low-density lipoprotein-cholesterol (LDL-C) as
previously described [53, 54].
Statistical analysis
The data are expressed as the mean ± SEM. One-way
ANOVA was used for multiple comparisons (GraphPad,
San Diego, CA, USA). Dunnett’s test was applied if a
significant difference was observed among the treated
groups. A value of p < 0.05 was considered statistically
significant.
Results
Effect of Kiom-18 on VSMC proliferation and early signal
phosphorylation
To determine the effect of Kiom-18 extract on VSMC
proliferation, a colorimetric WST-1 assay was performed.
Kiom-18 extract at a concentration of 30 and 50 μg/ml
significantly inhibited VSMC proliferation compared with
the PDGF-BB-stimulated control (Fig. 1a). To identify the
effect of Kiom-18 on VSMC proliferation via early signal
transduction pathways, we examined the activation of
PLCγ1, Akt, p38, ERK1/2, or JNK; however, no difference
was observed in the phosphorylation of early signal path-
ways in the presence of Kiom-18 (Fig. 1b). These results
suggest that Kiom-18 has anti-proliferative activity
through its downstream effects, although not with regard
to early signal transduction pathways, such as the arrest of
cell cycle progression, the suppression of cell cycle-related
proteins, or the expression of cyclin-dependent kinase
inhibitors (CKIs).
Effect of Kiom-18 on DNA synthesis and cell cycle
progression
By [3H]-thymidine incorporation, Kiom-18 extract at
concentrations of 5, 10, 30, and 50 μg/ml suppressed by
26.7 ± 2.5, 40.0 ± 3.4, 52.9 ± 2.2, and 58.6 ± 3.7 % compared
to the PDGF-BB-stimulated control, respectively (Fig. 2a).
The results shown in Fig. 2b demonstrate that cell cycle
progression was synchronized by the addition of PDGF-
BB. This result indicates the arrest of the cell cycle at the
transition from G0/G1 to the S phase after treatment with
Kiom-18 extract because the result matched the inhibition
effect on DNA synthesis.
Effects of Kiom-18 on cell cycle-related proteins and p27
expression
To determine the molecular mechanism with regard to
the inhibitory effect of Kiom-18 on cell cycle progres-
sion, we investigated the inhibitory effect of Kiom-18 ex-
tract on CDK2, CDK4, cyclin D1, cyclin E1, PCNA
expression and Rb phosphorylation as positive regulatory
proteins. As shown in Fig. 2c, Kiom-18 significantly
inhibited the expression of CDK 2/4 and cyclin D1/E1,
the G0/G1 phase-related proteins. Kiom-18 also sup-
pressed Rb phosphorylation, which is a major compo-
nent of the molecular network that modulates the
restriction point in the cell cycle progression. Subse-
quently, the presence of the Kiom-18 extract inhibited
PCNA, which is synthesized by a gene that is triggered
by hyper-phosphorylated Rb in the early G0/G1 and the
S phases (Fig. 2c). We next investigated the effect of
Kiom-18 extract on p27 expression. Figure 3a shows that
Kiom-18 concentration-dependently increased the ex-
pression of p27, which is the negative regulatory protein
of kinase and cyclin, thereby arresting the cell cycle at
the G0/G1 phase [55].
Additionally, based on the immunofluorescence level
of p27 expression, Kiom-18 extract at doses of 30 and
50 μg/ml increased by approximately 2.6- and 2.3-fold,
respectively, compared to the PDGF-BB-stimulated
control (Fig. 3b and c). This result, along with the
immunoblot results, demonstrates that the cell cycle at
the G0/G1 phase was suppressed by the presence of the
Kiom-18 extract.
Effects of Kiom-18 on LDL-receptor knockout mice
We used LDLr knockout mice to identify the immediate
effect of Kiom-18 extract in an atherosclerosis animal
model. The body weight of the mice fed a Western diet
for 14 weeks increased; however, that of the group
administered Kiom-18 extract significantly decreased
(Fig. 4a). As shown in Fig. 4b, Kiom-18 extract also
suppressed the fat weight (g), the food efficiency ratio
(100 × weight (g)/food intake (g)) [56], and neutrophils
(%). Additionally, the serum triglyceride (TG) level was
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Fig. 2 Effect of cinnamon extract on cell cycle progression and cell cycle-related proteins. VSMCs cultured in serum-starved medium were stimulated
with 25 ng/mL PDGF-BB and the effect in the presence of Kiom-18 extract (5–50 μg/ml) on the DNA synthesis (a) and the histogram data (b) for each
phase of the cell cycle is shown. The cell cycle progression data are representative of three independent experiments. Moreover, the effect of Kiom-18
extract on cell cycle regulatory proteins stimulated by PDGF-BB, including cyclin D1/E1, CDK2/4, Rb, and PCNA as negative regulatory molecules (c),
was measured using SDS-PAGE followed by immunoblotting. Total β-actin was used for normalization. These results were analyzed using densitometry;
the values represent the percentage of the control stimulated by PDGF-BB. All values are expressed as the mean ± SEM (n = 3). Significant differences
from the PDGF control (PDGF-stimulated) are shown by *p < 0.05 or **p < 0.01
Fig. 1 Effect of Kiom-18 extract on VSMC proliferation and early signal transduction. VSMCs cultured in serum-free medium were stimulated with
25 ng/mL PDGF-BB for 24 h, and the effect of various concentrations of Kiom-18 extract (5–50 μg/ml) was monitored. a Optimal densities were
determined at 450 nm using the WST-1 assay (n = 4). b The PDGF-induced phosphorylation of PLCγ1, ERK1/2, Akt, p38, and JNK was measured
using SDS-PAGE and immunoblotting. β-actin, ERK1/2, Akt, p38, and JNK were used for normalization (n = 3). These results were analyzed using
colorimetry (a) and densitometry (b); the values represent the percentage of the control stimulated by PDGF-BB. The values represent the
mean ± SEM. Significant differences from the PDGF control (PDGF-stimulated) are shown by **p < 0.01
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significantly inhibited by Kiom-18 extract compared
with the negative controls (Fig. 4c). These results suggest
that Kiom-18 extract has a suppressive effect on the
atherosclerotic conditions induced by Western dietary
consumption, including hyperlipidemia, inflammation,
and obesity. In the analysis of the atherosclerotic lesions,
Kiom-18 showed an inhibitory effect on neo-intimal
formation via VSMC hyperplasia in the aortic arch
(Fig. 4d). Moreover, Kiom-18 significantly reduced the
neo-intima/media area ratio compared with the control.
These findings indicate that the inhibition effect of
Kiom-18 is due to the anti-proliferative activity of
VSMCs as a result of the events described above.
Discussion
A large number of functional food products, several of
which have shown efficacy, have been developed and
marketed [57, 58]. To develop a functional supplement
(food) to prevent cardiovascular diseases, such as athero-
sclerosis, restenosis, stroke and myocardial infarction,
we conducted screening tests of traditional medicine
stored at the Korea Institute of Oriental Medicine. As a
result, Kiom-18, which is a novel composition, was pro-
duced as a functional supplement with considerations
for safety, efficacy and the supply of raw materials. The
Kiom-18 patent has been registered to gain the recogni-
tion of the Korean Intellectual Property Office (KIPO)
regarding the novelty and efficacy of this composition
(registration number: KR1461588).
In this study, we demonstrated that Kiom-18, a novel
composition of C. cassia, P. densiflora, C. longa and G.
glabra, prevents atherosclerosis through the anti-
proliferative effect on VSMCs via the regulation of cell
cycle-related proteins such as CDK2, CDK4, cyclin D1,
cyclin E1, Rb, and PCNA. These effects of the Kiom-18
extract were identified as preventive by increasing p27 ex-
pression, which has been recognized as a negative regula-
tor of cyclins and protein kinase, and in arresting the cell
cycle at the G0/G1 phase [13, 55]. Although it will require
further study, including in clinical trials, Kiom-18 extract
may be used as a functional food supplement to manage
atherosclerosis.
Atherosclerotic lesion formation is caused by VSMC
proliferation stimulated by cytokines and growth factors
secreted via endothelial cell dysfunction including the
inflammatory process [59, 60]. Ultimately, this pathway
is modulated by the transcriptional process of cell cycle-
regulatory proteins and genes promoting the prolifera-
tion of VSMCs [61]. Hence, the inhibition of VSMC
proliferation is considered an important target for the
treatment and prevention of atherosclerosis.
In the present study, we confirmed the anti-proliferative
activity of Kiom-18 extract on VSMCs, which significantly
inhibited PDGF-BB-stimulated VSMC proliferation
(Fig. 1a). VSMC proliferation was primarily regulated by
the phosphorylation of early signals, such as AKT, ERK1/
2, JNK, p38, and PLCγ1, stimulated by PDGF-BB [49, 62].
However, in this study, Kiom-18 extract had no direct ef-
fect on the phosphorylation of early signals, suggesting
that the anti-proliferative activity of Kiom-18 extract was
not due to its effect on early signaling pathways (Fig. 1b).
We next examined the effect of Kiom-18 in the down-
stream signal transduction of early signal phosphorylation,
including cell cycle progression, to determine the target of
its anti-proliferative effect [63]. Cell cycle progression in
VSMC proliferation is modulated by regulatory proteins,
such as cyclins, CDKs, pRb, and PCNA, which are consid-
ered important targets for the inhibition of proliferation
Fig. 3 Effect of Kiom-18 extract on the degradation of p27Kip1 expression stimulated by PDGF-BB. Quiescent VSMCs cultured in serum-deprived
medium were stimulated with 25 ng/mL PDGF-BB, and the inhibitory effect in the presence of Kiom-18 extract (5–50 μg/ml) on p27Kip1 expression
was examined using SDS-PAGE followed by immunoblotting (a), and immunofluorescence (b). Total β-actin and the fluorescence level of PI were used
for normalization. The immunoblotting (a) and immunofluorescence (c) were analyzed using densitometry; the values represent the percentage of the
stimulated control or the non-stimulated control. The results are an average of three similar, independent experiments and are expressed as the
mean ± SEM. Significant differences compared to the control stimulated by PDGF-BB are shown by **p < 0.01
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[11, 61, 64, 65]. Kiom-18 extract concentration-
dependently suppressed DNA synthesis via cell cycle
arrest at the G0/G1 phase (Fig. 2a and b). Among the
sequential phases of the cell cycle, the transition from the
G0/G1 phase to the S phase was mediated by CDK2/cyclin
E1 and CDK4/cyclin D1 complexes [66]; as a result, this
transition led to the phosphorylation of Rb. The Kiom-18
extract, according to the findings regarding cell cycle pro-
gression, significantly suppressed the phosphorylation of
Rb by inhibiting the CDK2/cyclin E1 and CDK4/cyclin D1
complexes, resulting in the decreased expression of PCNA
(Fig. 2c), which is synthesized as a product of the phos-
phorylated Rb-mediated gene in the cell cycle transition of
G0/G1 to S phase [67]. This transition at G0/G1 to S phase
was modulated by the CKIs such as INK4 and the Cip/Kip
family [11]. Among the Cip/Kip family, the Kiom-18
extract increased the expression of p27Kip1 in the im-
munoblotting assay (Fig. 3a), as it is a negative regulator
associated with protein kinase and cyclin of the cell cycle
at the G0/G1 phase [55]. Additionally, p27
Kip1 expression
was identified by an increase in the fluorescence level
while in the presence of the Kiom-18 extract (Fig. 3b),
which was significantly upregulated in correlation with
the immunoblotting results (Fig. 3c). These results indi-
cate that the anti-proliferative effect of Kiom-18 extract is
associated with the arrest of the cell cycle transition of G0/
G1 to S phase via the upregulation of p27
Kip1 expression.
This anti-proliferative activity of Kiom-18 extract is
caused by the modulation of cell cycle-related proteins
rather than by early signal transduction pathways [48, 68].
The enhanced proliferation of VSMCs contributed to
the formation of atherosclerotic plaque [69], and
Fig. 4 Effect of Kiom-18 extract on the formation of atherosclerotic plaque. The negative control (NC) mice were given unlimited access to a
normal diet (AIN-76A) for 2 weeks, and then they were fed a Western diet for 14 weeks (n = 4). The treatment group of mice were administered
Kiom-18 daily by gavage at a concentration of 1 g/kg and were fed a Western diet. The mice were measured for body weight (a), fat weight, liver
weight, food efficiency, neutrophils (b), and plasma biochemical parameters (c). Atherosclerotic plaque and neo-intima/media area ratio were analyzed
in the transverse section stained with H&E (d). The data are presented as the mean ± SEM. Significant differences compared to the negative control
(NC) are shown by *p < 0.05 or **p < 0.01
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although the KIOM-18 extract was used in a relatively
high concentration in LDLr knockout mice, the Kiom-18
extract suppressed the development of atherosclerotic
plaque in an animal model (Fig. 4). In previous studies
using p27Kip1 or ApoE-deficient mice, p27Kip1 expression
was reported to be an important factor in preventing
atherosclerosis [70, 71]. Even if p27Kip1 expression was
not directly identified in animal models, based on
previous reports, the inhibitory effect of Kiom-18 on the
formation of atherosclerotic plaque could be expected
by the upregulation of p27Kip1 expression. Moreover,
because the development of atherosclerotic plaque is
caused by the consumption of a high-fat diet, this animal
model demonstrated increases in body weight, fat
weight, liver weight, food efficiency, neutrophil count,
and blood chemical parameters. The Kiom-18 extract
significantly inhibited the body weight (Fig. 4a), fat
weight, food efficiency ratio (%), neutrophils (by % of
WBC differential counting) (Fig. 4b), and TG level
(Fig. 4c). These results indicate that Kiom-18 extract has
preventive effects in a high-fat-induced atherosclerosis
animal model.
Conclusion
Our results demonstrate that Kiom-18 extract inhibited
the formation of atherosclerotic plaque by inhibiting
VSMC proliferation through a G0/G1 arrest, which
upregulated the p27Kip1 expression. Therefore, we cau-
tiously anticipate that Kiom-18 extract may be used as a
functional food supplement or as a preventive agent to
manage atherosclerosis.
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